3rd annual global summit on genitourinarydavaonc.com/.../05/glob_gubanff_brochure_04182019.pdf ·...
TRANSCRIPT
3rd Annual Global Summit on
GENITOURINARYO CTOBER 10-13 , 2019BANFF | CANADA
MALIGNANCIES
3rd Annual Global Summit on
MALIGNANCIES AGENDAGENITOURINARY
O CTOBER 10-13 , 2019BANFF | CANADA
Thursday, October 10, 20195:45 PM Welcome and Introductions
KEYNOTE ADDRESS6:00 PM GU Malignancies: Perspectives and a Peer Into
the Future
SETTING THE STAGE6:30 PM What are the Practice Changes in 2019 for
Advanced Prostate Cancer?6:45 PM What are the Practice Changes in 2019 for
Metastatic RCC?7:00 PM What are the Practice Changes in 2019 for
Bladder Cancer?7:15 PM Moving Forward with Immunotherapy in GU
Malignancies7:30 PM The Era of Personalized Therapy for GU Tumors7:45 PM DISCUSSION8:00 PM ADJOURN TO WELCOME RECEPTION
Friday, October 11, 20196:00 AM BREAKFAST
ADVANCES IN IMAGING AND DIAGNOSIS7:00 AM Blue Light Flexible Cystoscopy with
Hexaminolevulinate for Surveillance of Bladder Cancer
7:15 AM PET Imaging in Prostate Cancer7:30 AM Challenges with RCC Type 1 and Type 2
Pathology Diagnosis7:45 AM Subtyping RCC on Imaging - The Role of
Radiologist8:00 AM Modeling Cost Effectiveness of Biomarker Based
Approaches to Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
8:15 AM Biotech Showcase8:30 AM DISCUSSION
THE ROLE OF SURGERY IN GU MALIGNANCIES
9:00 Optimal Timing for Radical Cystectomy After Neoadjuvant Chemotherapy
9:15 Radical Prostatectomy in Metastatic Disease9:30 Discussion
10:00 BREAK
IMMUNOTHERAPY IN GU MALIGNANCIES10:15 AM Maximizing Clinical Response to Immune
Checkpoint Therapy in GU Malignancies10:30 AM Current Data and Future Trials for PD-1/PD-L1
Inhibitors for Bladder Cancer10:45 AM Is There a Future for Immunotherapy in Prostate
Cancer?11:15 AM Biotech Showcase11:30 AM DISCUSSION AND CASE STUDIES12:00 PM ADJOURN
CURRENT UNDERSTANDING OF TKI IN RCC5:00 PM How do we Optimize the Effectiveness of VEGF
Inhibitors?5:15 PM The Role of Sequencing in TKIs5:30 PM DISCUSSION
THE SPECTRUM OF METASTATIC DISEASE IN PROSTATE CANCER
5:45 PM Management of Metastatic Castrate-sensitive Prostate Cancer
6:00 PM Does Treating the Primary Make a Difference in Metastatic Disease?
6:15 PM DISCUSSION
LEARNING FROM GENOMICS AND BIOMARKERS
6:30 PM Emerging Biomarkers and Imaging Tests to Improve Prostate Cancer Diagnostics
6:45 PM Genetic Heterogeneity in Kidney Cancer7:00 PM Genomic Classification in Localized Disease:
How can it Improve Outcomes?7:15 PM Molecular Landscape of non-Muscle Invasive
Versus Muscle Invasive Bladder Cancer7:30 PM Utilizing Genomics for the Selection of Systemic
Therapy7:45 PM DISCUSSION8:15 PM ADJOURN
3rd Annual Global Summit on
MALIGNANCIES AGENDAGENITOURINARY
O CTOBER 10-13 , 2019BANFF | CANADA
Saturday, October 12, 20196:00 AM BREAKFAST
TARGETED THERAPY IN BLADDER CANCER7:00 AM Targeting FGFR and mTOR in Bladder Cancer7:15 AM Targeting DNA Repair Genes in Bladder Cancer7:30 AM Taking Advantage of Nectin-4 Expression in
Bladder Cancer with ADCs7:45 AM Updates in Management of Urothelial Cancer8:00 AM DISCUSSION
BLADDER PRESERVATION THERAPY8:15 AM Match Pair Analysis of Cystectomy Compared to
Tri-Modality Therapy8:30 AM Curative Treatments of Invasive Bladder Cancer
Using Combined Modality Therapy9:00 AM Combining Immunotherapy and Radiation
Therapy in Bladder Cancer9:15 AM DISCUSSION
TARGETING AR IN CRPC: A MAJOR THERAPEUTIC CHALLENGE
9:30 AM AR Agents in non-Metastatic CRPC9:45 AM Biologic Rationale for Next-generation AR
Inhibitors10:00 AM Approaches to Block Persistent AR Function in
Metastatic CRPC10:15 AM An Androgen Receptor PROTAC Degrader for
Prostate Cancer10:30 AM DISCUSSION10:45 AM BREAK
MOVING BEYOND HORMONE RECEPTORS IN PROSTATE CANCER10:55 AM PARP inhibitors in Prostate Cancer11:10 AM Alterations in AR Signaling in Prostate Cancer
Development and Progression11:25 AM CDK4/6 Inhibition as Novel Therapeutic Strategy
for Metastatic Prostate Cancer11:40 AM Biotech Showcase11:55 AM DISCUSSION AND CASE STUDIES12:30 PM ADJOURN
QUALITY OF LIFE AND OUTCOME CONSIDERATIONS FOR GU MALIGNANCIES
5:00 PM How can PRO Drive Drug Development and Standards of Care?
5:15 PM Emerging Quality of Life Trends with Early Use of Novel Antiandrogen Therapies in Advanced Prostate Cancer
5:30 PM Improving Real World Outcomes in Bladder Cancer
5:45 PM Integrating Lifestyle Changes and Exercise into Prostate Cancer Care
6:00 PM DISCUSSION
COMBINATION APPROACHES FOR IMMUNOTHERAPY
6:15 PM Combination Therapy Targeting CTLA-4 and PD-1/PD-L1: Risks and Benefits for RCC
6:30 PM Immunotherapy Combination Approaches with Chemotherapy and Targeted Therapies in Bladder Cancer
6:45 PM Biotech Showcase7:00 PM Biotech Showcase7:15 PM DISCUSSION
PRACTICAL CONSIDERATION FOR IMMUNOTHERAPY
7:30 PM Managing Immunotherapy Toxicity in Bladder Cancer
7:45 PM Treatment After Checkpoint Therapy, What do we do Post Immunotherapy?
8:00 PM DISCUSSION 8:15 PM ADJOURN
Sunday, October 13, 20196:00 AM BREAKFAST
ORAL ABSTRACTS7:00 AM Oral Abstract 17:15 AM Oral Abstract 27:30 AM Oral Abstract 37:45 AM Oral Abstract 48:00 AM Oral Abstract 58:15 AM Oral Abstract 68:30 AM MEETING CONCLUDES
3rd Annual Global Summit on
GENITOURINARYMALIGNANCIES
For more imformation visit omionc.com